Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of low-dose atropine ophthalmic solution for pediatric myopia progression
2024-516315-24-00Phase 3Authorised
- Sponsor
- Ocumension Biotech
- Start
- May 2022
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 8
01
Overview
Phase 3, randomised, double-blind trial in myopia comparing OT-101 with Placebo (2 arms). Planned start May 2022; status: authorised.
02
Drugs
trabedersen
03
Conditions
myopia
Beyond the preview
Go deeper on 2024-516315-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516315-24-00.